The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class ...

Omvoh was approved for its first IBD indication, moderately to severely active ulcerative colitis (“UC”), in 2023. The drug is currently approved for UC in 44 countries.

Omvoh has possible interactions with certain vaccines. Examples include the chickenpox vaccine and the nasal spray flu vaccine (FluMist). Talk with your doctor to avoid potentially harmful effects ...

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

It is not known whether Omvoh (mirikizumab-mrkz) is safe to receive while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy may ...

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Omvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitis INDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli ...

Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.